首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin
【24h】

Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin

机译:在设计局部用聚合物成膜系统以持续将药物输送到皮肤时需要考虑配方因素

获取原文
获取原文并翻译 | 示例
       

摘要

Polymeric film-forming systems (FFSs) are potential drug delivery systems for topical application to the skin. The FFSs form thin and transparent polymeric films in situ upon solvent evaporation. Their application convenience and cosmetic attributes, superior to conventional semi-solids, may offer improved patient compliance. This study represents the first phase of an investigation into the use of FFSs for prolonged dermal drug delivery. FFS formulations were distinguished based on their ability to sustain the release of betamethasone 17-valerate (BMV) in vitro over 72 h. The effect of film-forming polymer (hydrophilic: hydroxypropyl cellulose (Klucel (TM) LF); hydrophobic: polymethacrylate copolymers (Eudragit (R) NE and Eudragit (R) RS), and polyacrylate copolymer (Dermacryl (R) 79) was first determined, and then the impact of incorporation of plasticisers (triethyl citrate, tributyl citrate, and dibutyl sebacate) was examined. The Klucel film released a significantly higher amount of BMV than the hydrophobic FFS, 42 versus 4 mu g/cm(2), respectively. The release was increased when a plasticiser was incorporated, and with higher enhancement ratios achieved with the more lipophilic plasticisers. In conclusion, the results show that FFSs can sustain drug release (hence representing useful systems for prolonged dermal therapy) and emphasise the importance of the formulation on drug delivery, with the type of polymer being of greatest significance. (C) 2015 Elsevier B.V. All rights reserved.
机译:聚合物成膜系统(FFS)是潜在的药物输送系统,可局部应用于皮肤。 FFS在溶剂蒸发后原位形成薄而透明的聚合物薄膜。它们的应用方便性和美容特性优于常规半固体,可改善患者的依从性。这项研究代表了使用FFS延长皮肤药物递送的调查的第一阶段。 FFS配方基于在72小时内维持体外倍他米松17-戊酸酯(BMV)释放的能力而著称。首先是成膜聚合物(亲水性:羟丙基纤维素(Klucel TM LF);疏水性:聚甲基丙烯酸酯共聚物(Eudragit(R)NE和Eudragit(R)RS),聚丙烯酸酯共聚物(Dermacryl(R)79)的作用。确定,然后检查掺入增塑剂(柠檬酸三乙酯,柠檬酸三丁酯和癸二酸二丁酯)的影响,Klucel膜释放的BMV比疏水性FFS高得多,分别为42和4μg / cm(2),结论:结果表明,FFS可以维持药物释放(因此代表了长期皮肤治疗的有用系统),并强调了重要性(C)2015 Elsevier BV保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号